Results Healthcare is pleased to announce that it has advised SQN Clinical, one of the largest data focused specialty contract research companies in Europe, on its acquisition by Veristat, a scientific-minded global clinical research organisation headquartered in the US.
SQN Clinical successfully supports the needs of global pharmaceutical, biotechnology, medical device, and animal health partners with innovative clinical development capabilities including a full spectrum of trial, data, and project management solutions powered by robust statistical analysis and reporting. The acquisition adds more than 80 employees, increasing Veristat’s European footprint and bolstering one of Veristat’s most sought after service areas, solidifying its position as a premier provider of world class biometrics solutions.
This transaction further cements the firm’s position as the leading advisor to fast-growth CRO businesses having recently advised Charterhouse on its investment in Phastar and AdmeScope on its acquisition by MercachemSyncom.
Karen Grover, Director of SQN Clinical:
The acquisition by Veristat enhances our capabilities and services to proactively address the increased demand from our sponsors. We have a shared reputation for scientific excellence and a shared passion for teamwork to support consistent service delivery and the highest quality outcomes.